Designing and launching public-private consortium to address the challenges of multicancer early detection
A new frontier in cancer screening is leveraging liquid-based detection, which look for signals of cancer in blood, urine, or stool samples, to create multi- rather than single-cancer screens. For those organizations focused on advancing multicancer early detection (MCED), the ambition is to develop blood tests, that could potentially be ordered annually, to screen healthy individuals for early signals of cancer, catch cancer earlier, and ultimately save more lives.
Industry, clinicians (primary and specialty care), patient advocates, payers, and other experts in the healthcare community, supported by Tapestry, seek to design and launch a multistakeholder public-private consortium to address the challenges related to MCED. Specifically, these include questions on assessing the efficacy, value, cost, benefit, and sustainability of these technologies to the health system, as well as defining the evidence needed to support the use of these technologies.
Throughout the second half of 2020, Tapestry Networks engaged with stakeholders in discussions to understand the key concerns facing the adoption of MCED and established the need for a focused and inclusive consortium to address these issues. This work culminated in the December 2020 MCED Forum, where participants coalesced around what approaches could be taken by a multistakeholder, public-private consortium to address MCED challenges and laid the groundwork for such a consortium to take shape.